# Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients

> **NCT04610502** · PHASE2 · COMPLETED · sponsor: **Caja Costarricense de Seguro Social** · enrollment: 26 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** Administration of Equine immunoglobulin anti SARS-CoV-2

## Key facts

- **NCT ID:** NCT04610502
- **Lead sponsor:** Caja Costarricense de Seguro Social
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-06
- **Primary completion:** 2020-10-06
- **Final completion:** 2020-12-06
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2021-03-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04610502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04610502, "Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04610502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*